Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The Landscape of Vascular Endothelial Growth Factor Inhibition in Retinal Diseases.
Invest Ophthalmol Vis Sci
January 2025
John F. Hardesty, MD, Department of Ophthalmology and Visual Sciences, Washington University School of Medicine in St. Louis, St. Louis, Missouri, United States.
Ever since the US Food and Drug Administration (FDA) approved the first vascular endothelial growth factor (VEGF) antagonist 2 decades ago, inhibitors of VEGF have revolutionized the treatment of a variety of ocular disorders involving pathologic neovascularization and retinal exudation. In this perspective, we evaluate the current status of anti-VEGF therapies and the real-world challenges encountered with maintaining therapeutic outcomes. Finally, we describe novel VEGF-based and combinatorial approaches that are in clinical development.
View Article and Find Full Text PDF[Treatment algorithm following first-line therapy failure in metastatic prostate cancer].
Urologie
January 2025
Klinik für Urologie, Campus Lübeck, Universitätsklinikum Schleswig-Holstein, Lübeck, Deutschland.
This article provides a comprehensive overview of the current treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) following the failure of first-line therapy. Although significant progress has been made in the primary treatment of hormone-sensitive prostate cancer, the management of mCRPC remains a clinical challenge. The article outlines the diagnostic criteria for mCRPC, which can be confirmed through biochemical progression and imaging techniques.
View Article and Find Full Text PDFMOMENT registry: Patients with advanced non-small-cell lung cancer harboring exon 14 skipping treated with systemic therapy.
J Comp Eff Res
January 2025
Department of Epidemiology, Merck Healthcare KGaA, Darmstadt, Germany.
exon 14 ex14) skipping occurs in 3-4% of non-small-cell lung cancer (NSCLC) cases. Low frequency of this alteration necessitated open-label, single-arm trials to investigate MET inhibitors. Since broad MET biomarker testing was only recently introduced in many countries, there is a lack of historical real-world data from patients with ex14 skipping NSCLC receiving conventional therapies.
View Article and Find Full Text PDFPerceived Burnout Among Underrepresented Minority Physician Assistant/Associate Educators in the United States.
J Physician Assist Educ
January 2025
Daytheon Sturges, PhD, MPAS, PA-C, MCHES, is an associate professor, vice chair-Justice, Equity, Diversity, & Inclusion (JEDI), Department of Family Medicine. He is also an associate program director-Regional Affairs and JEDI, MEDEX Northwest at School of Medicine, University of Washington, Seattle, WA.
Introduction: There is a keen interest regarding burnout in academic medicine with an existing need for more studies. The priority population were underrepresented physician assistant/associate (PA) educators in the United States. The purpose was to determine external/internal contributors leading to perceived burnout; investigate whether primary/secondary appraisal inform coping strategies; and determine whether there was an existing relationship between demographic factors and emotional exhaustion (EE).
View Article and Find Full Text PDFCosmetic surgery among women - a cross-sectional study.
Tidsskr Nor Laegeforen
January 2025
Institutt for psykologi, Oslo Nye Høyskole.
Background: Studies from 2003 and 2008 indicated that 7-8 % of adult women in Norway had undergone cosmetic surgery. As there is little research available on the current situation, the main purpose of this study was to map the use of, desire for and social acceptance of cosmetic surgery. We also wanted to identify differences in demographic and psychosocial factors between women who have undergone cosmetic surgery, those who desire such surgery and those who do not.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!